News

 

NEWS

Encoded Genomics, Xcell Bio among those to benefit from Illumina Accelerator’s $40M

Illumina today announced that its startup accelerator has secured $40 million from Viking Global Investors to fund promising genomic firms. Accelerator graduates that raise between $1 million and $5 million in new capital will receive additional dollar-for-dollar match funding from Illumina Accelerator Boost Capital. Read more at GenomeWeb

Read more

Neopeutics Wins 2015 North America Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as […]

Read more

Symic Adds Expertise to its Board

Symic Biomedical announced today the appointment of Barbara Yanni and William J. Newell to its board of directors. Mr. Newell is the CEO of Sutro Biopharma, Inc. which has entered into a strategic collaboration and acquisition option with Celgene regarding their therapeutic technology platform. Ms. Yanni retired in 2014 from Merck & Co., Inc. where she was most recently Vice […]

Read more

Amarantus to Present Positive Alzheimer’s Disease Biomarker Data

Amarantus announced that its abstract titled “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” was accepted for poster presentation at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.  Read the press release at […]

Read more

MedGenome to Raise $15M in Second Round of Funding

MedGenome, backed by Mu Sigma co-founders Dhiraj Rajaram and Ambiga Dhiraj, is looking to raise $15 million in a second round of funding to set up additional genome test labs. The clinical research and diagnostics firm is seeking a valuation of more than $100 million, a near ten-fold jump from last year, when it raised $4 million in its first […]

Read more

Amarantus Inks Alzheimer’s Biomarker Test Deal with Anavex

Amarantus BioScience Holdings today said that it has signed a deal to provide biomarker test services to Anavex Life Sciences for studies of that firm’s Alzheimer’s drug candidate. Under the deal, Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69 in specific sub-populations of peripheral […]

Read more

Senior Management Changes at Assembly Biosciences

Co-founder Derek Small succeeds Russell H. Ellison, MD, as CEO, as had been agreed in the merger last year that established Assembly. Small remains President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. Read the press release at Globe […]

Read more

John Mulcahy, SiteOne Therapeutics

Developing a non-addictive painkiller to compete with opiates Mission Bay Capital portfolio company John Mulcahy is co-founder and vice-president of research at SiteOne Therapeutics, a company developing a non-addictive oral replacement for narcotic pain medications such as oxycodone and Vicodin. SiteOne recently won a $1.4M SBIR grant and raised $1.5M in private funding, including an investment by QB3’s fund Mission […]

Read more

Colleen Cutcliffe, Whole Biome

Improving human health by sequencing and analyzing the microbiome and developing targeted therapies Colleen Cutcliffe is co-founder and CEO of Whole Biome, a company working with the Mayo Clinic and others to analyze the microbiome—the community of microorganisms that lives on and in our bodies—and to develop therapies that use the microbiome to improve human health. Whole Biome, which has […]

Read more

Uri Lopatin, Assembly Biosciences

Targeting the hepatitis B virus Ramen to reverse merger in under two years. Uri Lopatin co-founded Assembly Pharmaceuticals in 2012, first working from home and then riding his bicycle to our incubator. At one point he literally ate ramen noodles for two months straight. But less than two years later, his startup merged with Ventrus Biosciences to form Assembly Biosciences, […]

Read more
Page 8 of 9« First...56789

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter